SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community discusses a recent spike and potential catalysts. Bullish sentiment is fueled by speculation around a possible ETF, with some anticipating a significant price increase. Others are cautioning against getting caught up in hype and promoting alternative coins.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

$KENDU.X is gaining attention as community members highlight its strong, active community and real-world applications. Discussions revolve around the increasing holder count, dedicated community initiatives, and the potential for significant growth. The community emphasizes its organic growth and real-world brand building.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as the community rallies around its position as the first meme coin on Bitcoin, emphasizing its fair launch and strong community-driven growth. Discussion highlights its unique utility in strengthening the Bitcoin network through miner fees, setting it apart from other meme coins. Some believe $DOG.X has the potential to outperform other meme coins like $DOGE.X.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending due to positive updated Phase 3 HARMONi data for its lung cancer drug, ivonescimab, sparking optimism about its potential. The community is focused on the drug's OS benefit and its competitive efficacy compared to existing treatments, while also debating the validity and interpretation of trial data. Some investors are speculating about a potential acquisition or partnership, particularly with AstraZeneca, driving further interest in the stock.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

$BROKE.X is trending due to its active community and ongoing development, including a soon-to-be-released staking app and upcoming token burns. Community members are actively discussing its strong performance relative to other cryptos and anticipating the new staking utility. The project's dedicated developer and engaged community are key talking points.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

The crypto community is focused on the $DOG memecoin on the Bitcoin network, highlighting its fair launch and strong community. Many believe $DOG has the potential to become the leading memecoin on Bitcoin, even suggesting it could surpass $DOGE. Discussions also involve its listing on major exchanges like Kraken and its role within the Bitcoin Runes ecosystem.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is trending amid community speculation of a potential buyout offer from Nestlé, fueled by reports of a substantial per-share offer that could trigger a major short squeeze given the stock's high short interest. The community is weighing the credibility of the reports, while also considering the implications of recent leadership changes and an upcoming conference presentation. Some investors believe a deal is imminent, while others are waiting for official confirmation and evaluating the potential for milestone payments.

Concordium is a public, permissionless Layer 1 blockchain designed for businesses that require regulatory compliance without sacrificing privacy. Concordium was among the first to mandate identity verification at the blockchain consensus level while integrating zero-knowledge proofs (ZKPs) for selective disclosure. Launched in 2018, it embeds encrypted identity into every transaction at the protocol level, enabling accountability while preserving user confidentiality.  The project is backed by industry leaders from Volvo, IKEA, and Credit Suisse, among others, and aims to make blockchain adoption seamless for enterprises. Concordium has secured €52M in funding and partnered with Geely, a global automaker and co-owner of Volvo Cars, Volvo AB, and Daimler.  The newly appointed CEO and Executive Management team have revealed a focused strategic direction to double down on enabling stablecoin issuers, financial institutions, and payment providers to accelerate real-world adoption. With stablecoin settlement volumes projected to reach $300 billion per day by 2025, Concordium delivers a blockchain infrastructure uniquely suited for secure, programmable money solutions.

Concordium

Concordium is trending as the community discusses its potential as a turnaround play, highlighting its focus on PayFi and stablecoins. Some users point to a gradual upward movement as a positive sign, while others speculate about future price levels. The discussion also involves the team's background and potential partnerships.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as the community discusses its potential breakout, fueled by comparisons to DOGE's 2021 run and anticipation for its upcoming game release. Optimistic investors are accumulating, citing strong fundamentals, licensing potential, and endorsements like Matt Gaetz's investment, while some express concern over recent price action and broader market correlation.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to a recent land sale agreement, potentially boosting its NAV, which has captured the attention of traders. The stock's low float is fueling discussions of a potential squeeze, with community members actively watching for breakout levels. Some are betting on a significant upward move, drawing comparisons to other low-float runners.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street analysts downgraded Regulus Therapeutics on Wednesday following its acquisition by Swiss drugmaker Novartis, citing limited room for upside after the deal valued Regulus at up to $1.7 billion.JonesResearch cut its rating to ‘Hold’ from ‘Buy’ and lowered its price target to $7 from $8, calling the offer “highly favorable” in light of Regulus’ upcoming Phase 3 trial financing needs, according to The Fly.Canaccord Genuity also&nbsp;reportedly downgraded the stock to ‘Hold,’ slashing its target to $11 from $28.&nbsp;Meanwhile,&nbsp;Wells Fargo reportedly cut its rating on Regulus to ‘Equal Weight’ from ‘Overweight,’ raising its target to $9 from $6 to reflect the contingent value right (CVR) component. Leerink Partners and Oppenheimer issued similar downgrades.Under the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/regulus-therapeutics-stock-rockets-on-novartis-buy-offer/chXTfRKRbiP">agreement</a>, Regulus shareholders will receive $7 per share in cash and an additional $7 via a CVR, contingent on U.S. regulatory approval of its lead candidate, farabursen.&nbsp;The upfront payment represents a 108% premium to Regulus’ April 29 closing price and a 274% premium to its 60-day volume-weighted average.&nbsp;The transaction, unanimously approved by both companies’ boards, is expected to close in the second half of 2025, pending regulatory approvals and majority shareholder tender.Shares of Regulus surged to their highest levels since 2021 following the news and are up 6.4% year-to-date, while Novartis has gained 4.8%, both outperforming broader markets.The Dow is down 4.1%, the S&amp;P 500 has lost 5.1%, and the Nasdaq is off 1.6% over the same period.On Stocktwits, 24-hour message volume for Regulus jumped by 2,863% amid “extremely bullish” sentiment.One user congratulated Regulus shareholders, particularly recent buyers, and suggested that the growing interest in rare diseases could make companies like Protalix BioTherapeutics, Zevra Therapeutics, and Esperion Therapeutics potential targets going forward.<stembedurl>https://stocktwits.com/OldManLogan/message/613115970</stembedurl>Another Stocktwits user speculated that Regulus shares could double from current levels, fueled by FDA-related optimism and the potential for a competing bid to top Novartis' offer.<stembedurl>https://stocktwits.com/ST_Tropez_Trading/message/613203730</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regulus Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead

Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a higher bid or FDA-driven gains.

Equity

Shares of biopharmaceutical company Regulus Therapeutics Inc. (RGLS) shot up 138% at the opening bell on Wednesday after Swiss drugmaker Novartis agreed to acquire the firm for up to $1.7 billion.As per the terms of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.regulusrx.com/2025-04-30-Regulus-Therapeutics-Enters-into-Agreement-to-be-Acquired-by-Novartis-AG">deal</a>, Novartis, through a subsidiary, will initiate a tender offer to acquire all of Regulus' outstanding shares for an initial price of $7.00 per share or $800 million. The initial per-share price represents a premium of 108% to Regulus' closing price on April 29.Regulus shareholders will also receive a contingent value right (CVR) of $7.00 per share if its lead product candidate, farabursen, receives regulatory approval.The total consideration, including the CVR, would be approximately $1.7 billion.Regulus’ farabursen is an investigational microRNA inhibitor designed to reduce the growth of cysts and kidney size, as well as delay progression of disease severity in a severe kidney disease called autosomal dominant polycystic kidney disease (ADPKD).Novartis President Shreeram Aradhye noted that there are limited treatment options currently available for ADPKD.“The team at Regulus has done meaningful foundational work with farabursen, and we look forward to investigating its potential further as we aim to bring a better treatment option to patients in need," he said.The transaction is expected to be completed in the second half of 2025. Until then, Regulus will continue to operate as a separate and independent company. Following the completion of the deal, Regulus will become an indirect wholly-owned subsidiary of Novartis.<a href="https://stocktwits.com/symbol/RGLS">RGLS stock</a> is up by 397% so far this year and by 237% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/humana-reports-upbeat-q1-earnings/chXT9duRbiT">Humana Reports Upbeat Q1 Earnings, Reaffirms Full-Year Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis

According to the terms of the deal, Novartis, through a subsidiary, will initiate a tender offer to acquire all of Regulus' outstanding shares for an initial price of $7.00 per share or $800 million.

Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference...

Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)

Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429) Regulus Therapeutics Announces...

Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences

Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences PR Newswire SAN...

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates PR Newswire SAN DIEGO, Nov...

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant...

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences PR Newswire SAN DIEGO, Aug...

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates PR Newswire SAN DIEGO, Aug...

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences PR Newswire SAN DIEGO, July...

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.

Current Price	$8.16
Prev Close	$8.14
Open	$8.15
Dividend Yield	0.00%
50-Day Moving Average	$7.51
Beta	1.14
Avg. Volume	2.41M
PE Ratio	-11.23

52-Week High	$8.35
52-Week Low	$0.8301
Market Capitalization	$564.95M
EPS (Annual)	-$0.8227
Price to Book	7.84
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

RGLS
Regulus Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RGLS News

RGLS Regulus Therapeutics Inc